E-drug: Re: New leadership in WHO (3)
----------------------------------------------------------
Dear colleagues,
A recent editorial in the British Medical Journal (BMJ 1998, 317: 296;
August 1, 1998) raises concern about the appointment of the new
executive director responsible for health technology and drugs. Michael
Scholtz, coming from the multinational pharmaceutical industry, will be
in charge of the action programme on essential drugs and has little
experience of the developing world. Scholtz was SmithKline Beecham
Biologicals' vice-president and director of marketing operation. Dr
Brundtland has portrayed the appointment as providing a liaison between
the industry and the WHO.
Greetings,
Mark Raijmakers
---
The site can be found at:
http://www.bmj.com/cgi/content/full/317/7154/296
BMJ 1998;317 ( 1 August ): Editor's choice: Two unlike people
Editorials
Change at last at WHO. But will the regions play ball?
News p 302
1.Mach A. Brundtland replaces top staff at the WHO. BMJ 1998; 317: 229.
See:
http://www.bmj.com/cgi/content/full/317/7153/229?ijkey=j6/giLFaEvEKk
Correction for Mach, BMJ 317 (7153) 229.
BMJ 1998;317:298 ( 1 August )
News, Correction
Brundtland replaces top staff at the WHO: The article (25 July, p 229)
stated that the Norwegian government was rumoured to have given "a
sizeable sum ($30m, £19m)" to help reform the World Health
Organisation. In fact the total amount contributed by Norway is less
than $2m--half of which will go towards the WHO renewal fund.
Related editorials in BMJ:
Change at last at WHO.
Fiona Godlee
BMJ 1998 317: 296. [Full text]
Other related articles in BMJ:
NEWS
Brundtland replaces top staff at the WHO.
Adrea Mach
BMJ 1998 317: 229. [Full text]